内容紹介
Clinical Analysis of Combination Chemotherapy Using High Dose Methotrexate, Rituximab, and Vincristine with or without Procarbazine for Elderly Patients with Diffuse Large B-Cell Lymphoma of the Central Nervous System
Summary
We studied the clinical effects of high-dose methotrexate(HD-MTX)combined with rituximab and vincristine in 5 elderly patients, aged 65-83 years, with diffuse large B-cell lymphoma of the central nervous system(DLBCL CNS). Patients aged 65-71 years were given 3.0 g/m2 of HD-MTX, while patients aged 75-83 years were given 1.5 g/m2 of the drug. All patients showed responses; 1 CR and 1 PR in MTX 3.0 g/m2 group, and 2 CRs and 1 PR in MTX 1.5 g/m2 group.
要旨
diffuse large B-cell lymphoma(DLBCL)で腫瘤性の中枢神経(CNS)浸潤を呈した65～83歳の高齢患者5例に対し,methotrexate(MTX)を75歳未満は3.0 g/m2,75歳以上は1.5 g/m2投与とするhigh-dose MTX(HD-MTX)のrituximabおよびvincristineとの併用による効果を検討し,MTX 3.0 g/m2群でCR 1例・PR 1例,MTX 1.5 g/m2群でCR 2例・PR 1例と全例に奏効を得た。MTX 1.5 g/m2のHD-MTX療法は75～83歳のDLBCLの腫瘤性CNS浸潤に安全に投与でき,効果が期待できる治療法と考えられる。
目次
Summary
We studied the clinical effects of high-dose methotrexate(HD-MTX)combined with rituximab and vincristine in 5 elderly patients, aged 65-83 years, with diffuse large B-cell lymphoma of the central nervous system(DLBCL CNS). Patients aged 65-71 years were given 3.0 g/m2 of HD-MTX, while patients aged 75-83 years were given 1.5 g/m2 of the drug. All patients showed responses; 1 CR and 1 PR in MTX 3.0 g/m2 group, and 2 CRs and 1 PR in MTX 1.5 g/m2 group.
要旨
diffuse large B-cell lymphoma(DLBCL)で腫瘤性の中枢神経(CNS)浸潤を呈した65～83歳の高齢患者5例に対し,methotrexate(MTX)を75歳未満は3.0 g/m2,75歳以上は1.5 g/m2投与とするhigh-dose MTX(HD-MTX)のrituximabおよびvincristineとの併用による効果を検討し,MTX 3.0 g/m2群でCR 1例・PR 1例,MTX 1.5 g/m2群でCR 2例・PR 1例と全例に奏効を得た。MTX 1.5 g/m2のHD-MTX療法は75～83歳のDLBCLの腫瘤性CNS浸潤に安全に投与でき,効果が期待できる治療法と考えられる。